Puymirat, E <br/><br/>
Cost analysis of bivalirudin versus reference anticoagulants without GP IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention for acute coronary syndrome in routine clinical practice. Pompidou registry.  [electronic resource] 

 -  Annales de cardiologie et d'angeiologie  Apr 2013 
 - 89-94 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1768-3181 
<br/><br/><label>Standard No.: </label>10.1016/j.ancard.2012.10.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--economics<br/>Aged<br/>Aged, 80 and over<br/>Anticoagulants--economics<br/>Antithrombins--economics<br/>Cost-Benefit Analysis<br/>Drug Costs<br/>Female<br/>Heparin--economics<br/>Hirudins--economics<br/>Hospitals, University<br/>Humans<br/>Length of Stay--economics<br/>Male<br/>Middle Aged<br/>Paris<br/>Peptide Fragments--economics<br/>Percutaneous Coronary Intervention<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Prospective Studies<br/>Recombinant Proteins--economics<br/>Registries<br/>Treatment Outcome